Prices are updated after-hours


Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date

symbols : SRNE    crawled time : 04:00    save search

Sorrento Issues “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock
Published: 2023-01-30 (Crawled : 04:00) - globenewswire.com
SCLX | $0.8942 -23.57% -30.84% 2.8M twitter stocktwits trandingview |
| | O: 11.24% H: 1.94% C: -11.33%
BNPQF | $68.558 -13.4% 400 twitter stocktwits trandingview |
Finance
| | O: -0.16% H: 0.0% C: -1.3%
BNPQY | $34.25 -2.68% 180K twitter stocktwits trandingview |
Finance and Insurance
| | O: 0.33% H: 0.44% C: -0.59%
XYF | News | $3.78 -0.26% 0.0% 4.9K twitter stocktwits trandingview |
Finance
| | O: -0.51% H: 0.0% C: -2.84%
UBS J | $28.12 0.04% 0.0% 2.3M twitter stocktwits trandingview |
Finance
| | O: -0.42% H: 0.7% C: -0.33%
USB | $39.44 -0.2% -0.48% 9.9M twitter stocktwits trandingview |
Finance
| | O: -0.59% H: 1.59% C: 0.47%
MS | News 0 d | $90.26 0.2% 0.0% 6.7M twitter stocktwits trandingview |
Finance
| | O: -1.89% H: 1.66% C: 0.98%
DB | $15.8 0.83% -0.25% 7.6M twitter stocktwits trandingview |
Finance
| | O: -0.37% H: 0.67% C: -0.67%
SRNE | $0.028 -8.85% 42K twitter stocktwits trandingview |
Health Technology
| | O: -0.99% H: 1.0% C: -5.0%
AMAL | $21.575 0.4% 0.39% 80K twitter stocktwits trandingview |
Finance
| | O: -0.27% H: 1.46% C: 1.15%


Scilex Holding Company, a Sorrento Company, Announces That the FDA Has Granted Fast Track Designation for SP-103 (Lidocaine Topical System) 5.4%, Next Generation Triple Strength Formulation of ZTlido®, for the Treatment of Acute Low Back Pain (LBP)
Published: 2022-08-31 (Crawled : 04:00) - globenewswire.com
SRNE | $0.028 -8.85% 42K twitter stocktwits trandingview |
Health Technology
| | O: 5.15% H: 2.94% C: 0.49%

sp-103 ztlido treatment fda designation back granted fast track designation
Lee’s Pharmaceutical Announces its Anti-PD-L1 Antibody Socazolimab, Licensed From Sorrento Therapeutics, Receives Clearance to Start Phase 3 Trial as a First-line Treatment of Extensive-stage Small-Cell Lung Cancer
Published: 2021-03-08 (Crawled : 04:00) - globenewswire.com
SRNE | $0.028 -8.85% 42K twitter stocktwits trandingview |
Health Technology
| | O: 3.38% H: 0.76% C: -4.25%

treatment lung cancer cancer antibody license phase 3 trial clearance
Gainers vs Losers
64% 36%

Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M twitter stocktwits trandingview |
Finance

ZCMD | $2.86 108.76% 52.1% 2.3M twitter stocktwits trandingview |
Commercial Services

INVO | $1.555 104.6% 51.13% 5M twitter stocktwits trandingview |
Health Technology

ISPC | $0.437 105.16% 49.53% 37M twitter stocktwits trandingview |
Professional, Scientific, and T...

WLGS | News | $0.92 84.0% 45.65% 1.6M twitter stocktwits trandingview |

OST | $0.499 21.38% 45.26% 1.9M twitter stocktwits trandingview |

XPON | News | $3.1 60.62% 37.74% 17M twitter stocktwits trandingview |

TIRX | $0.7 44.39% 30.74% 58M twitter stocktwits trandingview |

BNTC | News | $6.92 44.17% 30.64% 3.5M twitter stocktwits trandingview |
Health Technology

GGE | $0.035 19.86% 29.3% 64M twitter stocktwits trandingview |


Your saved searches
Save your searches and get alerts when important news are released.